Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland
Chronic hepatitis C virus infection is a major cause of liver disease in Switzerland and carries a significant cost burden. Currently, only conservative strategies are in place to mitigate the burden of hepatitis C in Switzerland. This study expands on previously described modeling efforts to explor...
Gespeichert in:
| Veröffentlicht in: | PloS one Jg. 10; H. 6; S. e0125214 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
Public Library of Science
24.06.2015
Public Library of Science (PLoS) |
| Schlagworte: | |
| ISSN: | 1932-6203, 1932-6203 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Chronic hepatitis C virus infection is a major cause of liver disease in Switzerland and carries a significant cost burden. Currently, only conservative strategies are in place to mitigate the burden of hepatitis C in Switzerland. This study expands on previously described modeling efforts to explore the impact of: no treatment, and treatment to reduce HCC and mortality. Furthermore, the costs associated with untreated HCV were modeled.
Hepatitis C disease progression and mortality were modeled. Baseline historical assumptions were collected from the literature and expert interviews and strategies were developed to show the impact of different levels of intervention (improved drug cure rates, treatment and diagnosis) until 2030.
Under the historical standard of care, the number of advanced stage cases was projected to increase until 2030, at which point the annual economic burden of untreated viremic infections was projected to reach €96.8 (95% Uncertainty Interval: €36 - €232) million. Scenarios to reduce HCV liver-related mortality by 90% by 2030 required treatment of 4,190 ≥F2 or 3,200 ≥F3 patients annually by 2018 using antivirals with a 95% efficacy rate. Delaying the implementation of these scenarios by 2 or 5 years reduced the impact on mortality to 75% and 57%, respectively.
With today's treatment efficacy and uptake rates, hepatitis C disease burden is expected to increase through 2030. A substantial reduction in disease burden can be achieved by means of both higher efficacy drugs and increased treatment uptake. However, these efforts cannot be undertaken without a simultaneous effort to diagnose more infections. |
|---|---|
| AbstractList | Background Chronic hepatitis C virus infection is a major cause of liver disease in Switzerland and carries a significant cost burden. Currently, only conservative strategies are in place to mitigate the burden of hepatitis C in Switzerland. This study expands on previously described modeling efforts to explore the impact of: no treatment, and treatment to reduce HCC and mortality. Furthermore, the costs associated with untreated HCV were modeled. Methods Hepatitis C disease progression and mortality were modeled. Baseline historical assumptions were collected from the literature and expert interviews and strategies were developed to show the impact of different levels of intervention (improved drug cure rates, treatment and diagnosis) until 2030. Results Under the historical standard of care, the number of advanced stage cases was projected to increase until 2030, at which point the annual economic burden of untreated viremic infections was projected to reach €96.8 (95% Uncertainty Interval: €36 – €232) million. Scenarios to reduce HCV liver-related mortality by 90% by 2030 required treatment of 4,190 ≥F2 or 3,200 ≥F3 patients annually by 2018 using antivirals with a 95% efficacy rate. Delaying the implementation of these scenarios by 2 or 5 years reduced the impact on mortality to 75% and 57%, respectively. Conclusions With today’s treatment efficacy and uptake rates, hepatitis C disease burden is expected to increase through 2030. A substantial reduction in disease burden can be achieved by means of both higher efficacy drugs and increased treatment uptake. However, these efforts cannot be undertaken without a simultaneous effort to diagnose more infections. Chronic hepatitis C virus infection is a major cause of liver disease in Switzerland and carries a significant cost burden. Currently, only conservative strategies are in place to mitigate the burden of hepatitis C in Switzerland. This study expands on previously described modeling efforts to explore the impact of: no treatment, and treatment to reduce HCC and mortality. Furthermore, the costs associated with untreated HCV were modeled.BACKGROUNDChronic hepatitis C virus infection is a major cause of liver disease in Switzerland and carries a significant cost burden. Currently, only conservative strategies are in place to mitigate the burden of hepatitis C in Switzerland. This study expands on previously described modeling efforts to explore the impact of: no treatment, and treatment to reduce HCC and mortality. Furthermore, the costs associated with untreated HCV were modeled.Hepatitis C disease progression and mortality were modeled. Baseline historical assumptions were collected from the literature and expert interviews and strategies were developed to show the impact of different levels of intervention (improved drug cure rates, treatment and diagnosis) until 2030.METHODSHepatitis C disease progression and mortality were modeled. Baseline historical assumptions were collected from the literature and expert interviews and strategies were developed to show the impact of different levels of intervention (improved drug cure rates, treatment and diagnosis) until 2030.Under the historical standard of care, the number of advanced stage cases was projected to increase until 2030, at which point the annual economic burden of untreated viremic infections was projected to reach €96.8 (95% Uncertainty Interval: €36 - €232) million. Scenarios to reduce HCV liver-related mortality by 90% by 2030 required treatment of 4,190 ≥F2 or 3,200 ≥F3 patients annually by 2018 using antivirals with a 95% efficacy rate. Delaying the implementation of these scenarios by 2 or 5 years reduced the impact on mortality to 75% and 57%, respectively.RESULTSUnder the historical standard of care, the number of advanced stage cases was projected to increase until 2030, at which point the annual economic burden of untreated viremic infections was projected to reach €96.8 (95% Uncertainty Interval: €36 - €232) million. Scenarios to reduce HCV liver-related mortality by 90% by 2030 required treatment of 4,190 ≥F2 or 3,200 ≥F3 patients annually by 2018 using antivirals with a 95% efficacy rate. Delaying the implementation of these scenarios by 2 or 5 years reduced the impact on mortality to 75% and 57%, respectively.With today's treatment efficacy and uptake rates, hepatitis C disease burden is expected to increase through 2030. A substantial reduction in disease burden can be achieved by means of both higher efficacy drugs and increased treatment uptake. However, these efforts cannot be undertaken without a simultaneous effort to diagnose more infections.CONCLUSIONSWith today's treatment efficacy and uptake rates, hepatitis C disease burden is expected to increase through 2030. A substantial reduction in disease burden can be achieved by means of both higher efficacy drugs and increased treatment uptake. However, these efforts cannot be undertaken without a simultaneous effort to diagnose more infections. BackgroundChronic hepatitis C virus infection is a major cause of liver disease in Switzerland and carries a significant cost burden. Currently, only conservative strategies are in place to mitigate the burden of hepatitis C in Switzerland. This study expands on previously described modeling efforts to explore the impact of: no treatment, and treatment to reduce HCC and mortality. Furthermore, the costs associated with untreated HCV were modeled.MethodsHepatitis C disease progression and mortality were modeled. Baseline historical assumptions were collected from the literature and expert interviews and strategies were developed to show the impact of different levels of intervention (improved drug cure rates, treatment and diagnosis) until 2030.ResultsUnder the historical standard of care, the number of advanced stage cases was projected to increase until 2030, at which point the annual economic burden of untreated viremic infections was projected to reach €96.8 (95% Uncertainty Interval: €36 - €232) million. Scenarios to reduce HCV liver-related mortality by 90% by 2030 required treatment of 4,190 ≥F2 or 3,200 ≥F3 patients annually by 2018 using antivirals with a 95% efficacy rate. Delaying the implementation of these scenarios by 2 or 5 years reduced the impact on mortality to 75% and 57%, respectively.ConclusionsWith today's treatment efficacy and uptake rates, hepatitis C disease burden is expected to increase through 2030. A substantial reduction in disease burden can be achieved by means of both higher efficacy drugs and increased treatment uptake. However, these efforts cannot be undertaken without a simultaneous effort to diagnose more infections. Chronic hepatitis C virus infection is a major cause of liver disease in Switzerland and carries a significant cost burden. Currently, only conservative strategies are in place to mitigate the burden of hepatitis C in Switzerland. This study expands on previously described modeling efforts to explore the impact of: no treatment, and treatment to reduce HCC and mortality. Furthermore, the costs associated with untreated HCV were modeled. Hepatitis C disease progression and mortality were modeled. Baseline historical assumptions were collected from the literature and expert interviews and strategies were developed to show the impact of different levels of intervention (improved drug cure rates, treatment and diagnosis) until 2030. Under the historical standard of care, the number of advanced stage cases was projected to increase until 2030, at which point the annual economic burden of untreated viremic infections was projected to reach €96.8 (95% Uncertainty Interval: €36 - €232) million. Scenarios to reduce HCV liver-related mortality by 90% by 2030 required treatment of 4,190 ≥F2 or 3,200 ≥F3 patients annually by 2018 using antivirals with a 95% efficacy rate. Delaying the implementation of these scenarios by 2 or 5 years reduced the impact on mortality to 75% and 57%, respectively. With today's treatment efficacy and uptake rates, hepatitis C disease burden is expected to increase through 2030. A substantial reduction in disease burden can be achieved by means of both higher efficacy drugs and increased treatment uptake. However, these efforts cannot be undertaken without a simultaneous effort to diagnose more infections. Background Chronic hepatitis C virus infection is a major cause of liver disease in Switzerland and carries a significant cost burden. Currently, only conservative strategies are in place to mitigate the burden of hepatitis C in Switzerland. This study expands on previously described modeling efforts to explore the impact of: no treatment, and treatment to reduce HCC and mortality. Furthermore, the costs associated with untreated HCV were modeled. Methods Hepatitis C disease progression and mortality were modeled. Baseline historical assumptions were collected from the literature and expert interviews and strategies were developed to show the impact of different levels of intervention (improved drug cure rates, treatment and diagnosis) until 2030. Results Under the historical standard of care, the number of advanced stage cases was projected to increase until 2030, at which point the annual economic burden of untreated viremic infections was projected to reach €96.8 (95% Uncertainty Interval: €36 – €232) million. Scenarios to reduce HCV liver-related mortality by 90% by 2030 required treatment of 4,190 ≥F2 or 3,200 ≥F3 patients annually by 2018 using antivirals with a 95% efficacy rate. Delaying the implementation of these scenarios by 2 or 5 years reduced the impact on mortality to 75% and 57%, respectively. Conclusions With today’s treatment efficacy and uptake rates, hepatitis C disease burden is expected to increase through 2030. A substantial reduction in disease burden can be achieved by means of both higher efficacy drugs and increased treatment uptake. However, these efforts cannot be undertaken without a simultaneous effort to diagnose more infections. |
| Author | Müllhaupt, Beat Blach, Sarah Razavi, Homie Semela, David Negro, Francesco Bruggmann, Philip Bihl, Florian Lavanchy, Daniel |
| AuthorAffiliation | 2 Arud Centres for Addiction Medicine, Zürich, Switzerland 7 Divisions of Gastroenterology and Hepatology and of Clinical Pathology, University Hospital, Genève, Switzerland National Taiwan University Hospital, TAIWAN 3 Gastroenterology Department, Ospedale Cantonale, Bellinzona, Switzerland 1 Swiss HPB (Hepato-Pancreato-Biliary) Center and Department of Gastroenterology and Hepatology, University Hospital Zürich, Zürich, Switzerland 4 Center for Disease Analysis (CDA), Louisville, Colorado, United States of America 5 Consultant, Ruelle des Chataigniers 1, CH-1026 Denges VD, Switzerland 6 Division of Gastroenterology & Hepatology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland |
| AuthorAffiliation_xml | – name: 4 Center for Disease Analysis (CDA), Louisville, Colorado, United States of America – name: 1 Swiss HPB (Hepato-Pancreato-Biliary) Center and Department of Gastroenterology and Hepatology, University Hospital Zürich, Zürich, Switzerland – name: 3 Gastroenterology Department, Ospedale Cantonale, Bellinzona, Switzerland – name: National Taiwan University Hospital, TAIWAN – name: 2 Arud Centres for Addiction Medicine, Zürich, Switzerland – name: 5 Consultant, Ruelle des Chataigniers 1, CH-1026 Denges VD, Switzerland – name: 6 Division of Gastroenterology & Hepatology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland – name: 7 Divisions of Gastroenterology and Hepatology and of Clinical Pathology, University Hospital, Genève, Switzerland |
| Author_xml | – sequence: 1 givenname: Beat surname: Müllhaupt fullname: Müllhaupt, Beat – sequence: 2 givenname: Philip surname: Bruggmann fullname: Bruggmann, Philip – sequence: 3 givenname: Florian surname: Bihl fullname: Bihl, Florian – sequence: 4 givenname: Sarah surname: Blach fullname: Blach, Sarah – sequence: 5 givenname: Daniel surname: Lavanchy fullname: Lavanchy, Daniel – sequence: 6 givenname: Homie surname: Razavi fullname: Razavi, Homie – sequence: 7 givenname: David surname: Semela fullname: Semela, David – sequence: 8 givenname: Francesco surname: Negro fullname: Negro, Francesco |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26107467$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9UstuEzEUtVARfcAfILDEppsEv8Yes0CCqNCKIhY8tpbHvpM4moyDPUMFX4_TTKu2Qqxs3XvOuec-jtFBH3tA6Dklc8oVfb2OY-ptN9-W8JxQVjEqHqEjqjmbSUb4wZ3_ITrOeU1IxWspn6BDJilRQqoj9Olz9NCFfomHFeBzsN2wwrb3-MzFPm6Cw-_H5KHHsS3ZrR3CEDJe4B8hjRmHHn-9CsMfSF3hPEWPW9tleDa9J-j7h7Nvi_PZ5ZePF4t3lzNXMTnMnJCCSSGh4qC0beqW19YyoEBd65XinlWkAUYa6mrtBTS6pjUooL61vGr5CXq51912MZtpDtlQqSnhuuK0IC72CB_t2mxT2Nj020QbzHUgpqWxaQiuA9NSaKjVvGGsEtZWVoNvatEqWmbkFCtab6dqY7MB76Afku3uid7P9GFllvGXEaImWuoicDoJpPhzhDyYTcgOujIyiOPed6WFuq716gH03929uOvo1srNVgtA7AEuxZwTtLcQSszueG5kze54zHQ8hfbmAc2FoWw87voK3f_JfwHp081p |
| CitedBy_id | crossref_primary_10_1016_j_jhep_2016_02_030 crossref_primary_10_1016_j_jval_2017_10_005 crossref_primary_10_1016_j_jhep_2017_10_010 crossref_primary_10_1186_s12961_022_00824_3 crossref_primary_10_3390_jcm10194562 crossref_primary_10_1371_journal_pone_0155464 crossref_primary_10_1371_journal_pone_0272518 crossref_primary_10_1007_s12072_017_9820_3 crossref_primary_10_1111_liv_15111 crossref_primary_10_1111_jvh_12803 crossref_primary_10_1001_jamanetworkopen_2020_4192 crossref_primary_10_1016_j_cld_2017_03_012 crossref_primary_10_1080_17512433_2018_1447923 crossref_primary_10_1111_jvh_13005 crossref_primary_10_1111_jvh_12535 crossref_primary_10_1017_S0950268816001722 crossref_primary_10_1371_journal_pone_0209374 crossref_primary_10_1111_jvh_13892 |
| Cites_doi | 10.1007/s10620-006-9669-0 10.1002/hep.510310332 10.1038/474S18a 10.1053/gast.2002.33023 10.1111/j.1478-3231.2011.02539.x 10.1111/j.1525-1497.2005.0161.x 10.1002/hep.26590 10.1002/hep.26141 10.1056/NEJMoa1009370 10.1111/j.1469-0691.2010.03432.x 10.1093/cid/cit234 10.1093/ije/dym096 10.1093/pubmed/fdp067 10.2471/BLT.12.108282 10.1111/jvh.12247 10.2807/ese.13.21.18881-en 10.1002/hep.26218 10.1111/jvh.12248 10.2105/AJPH.90.10.1562 10.1093/heapol/czs058 10.1111/j.1465-3362.2009.00167.x 10.7326/0003-4819-144-10-200605160-00004 10.1097/00042737-200201000-00006 10.7326/0003-4819-156-4-201202210-00004 |
| ContentType | Journal Article |
| Copyright | 2015 Müllhaupt et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2015 Müllhaupt et al 2015 Müllhaupt et al |
| Copyright_xml | – notice: 2015 Müllhaupt et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2015 Müllhaupt et al 2015 Müllhaupt et al |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QG 7QL 7QO 7RV 7SN 7SS 7T5 7TG 7TM 7U9 7X2 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABJCF ABUWG AEUYN AFKRA ARAPS ATCPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU D1I DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB. KB0 KL. L6V LK8 M0K M0S M1P M7N M7P M7S NAPCQ P5Z P62 P64 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PTHSS PYCSY RC3 7X8 5PM DOA |
| DOI | 10.1371/journal.pone.0125214 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts Nursing & Allied Health Database Ecology Abstracts Entomology Abstracts (Full archive) Immunology Abstracts Meteorological & Geoastrophysical Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Agricultural Science Collection Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Materials Science & Engineering Collection ProQuest Central (Alumni) One Sustainability ProQuest Central UK/Ireland Advanced Technologies & Computer Science Collection Agricultural & Environmental Science Collection ProQuest Central Essentials - QC ProQuest SciTech Premium Collection Natural Science Collection Biological Science Collection ProQuest Central Technology Collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Materials Science Collection ProQuest Central Korea Engineering Research Database ProQuest Health & Medical Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Materials Science Database Nursing & Allied Health Database (Alumni Edition) Meteorological & Geoastrophysical Abstracts - Academic ProQuest Engineering Collection ProQuest Biological Science Collection Agricultural Science Database ProQuest Health & Medical Collection Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Engineering Database Nursing & Allied Health Premium Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts Environmental Science Database Materials Science Collection ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China Engineering Collection Environmental Science Collection Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Agricultural Science Database Publicly Available Content Database ProQuest Central Student ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Meteorological & Geoastrophysical Abstracts Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Engineering Collection Advanced Technologies & Aerospace Collection Engineering Database Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Agricultural Science Collection ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Environmental Science Collection Entomology Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Environmental Science Database ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic Meteorological & Geoastrophysical Abstracts - Academic ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) Materials Science Collection ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts ProQuest Engineering Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Agricultural & Environmental Science Collection AIDS and Cancer Research Abstracts Materials Science Database ProQuest Materials Science Collection ProQuest Public Health ProQuest Nursing & Allied Health Source ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Animal Behavior Abstracts Materials Science & Engineering Collection Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Agricultural Science Database MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Sciences (General) Economics Public Health |
| DocumentTitleAlternate | Economic Impact of Hepatitis C |
| EISSN | 1932-6203 |
| ExternalDocumentID | 1691039531 oai_doaj_org_article_f1eb1a93b2254aa5a9edb84f71610c72 PMC4480969 3725641911 26107467 10_1371_journal_pone_0125214 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Switzerland United States--US Colorado |
| GeographicLocations_xml | – name: Switzerland – name: Colorado – name: United States--US |
| GroupedDBID | --- 123 29O 2WC 53G 5VS 7RV 7X2 7X7 7XC 88E 8AO 8C1 8CJ 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ AAUCC AAWOE AAYXX ABDBF ABIVO ABJCF ABUWG ACCTH ACGFO ACIHN ACIWK ACPRK ACUHS ADBBV ADRAZ AEAQA AENEX AEUYN AFFHD AFKRA AFPKN AFRAH AHMBA ALMA_UNASSIGNED_HOLDINGS AOIJS APEBS ARAPS ATCPS BAIFH BAWUL BBNVY BBTPI BCNDV BENPR BGLVJ BHPHI BKEYQ BPHCQ BVXVI BWKFM CCPQU CITATION CS3 D1I D1J D1K DIK DU5 E3Z EAP EAS EBD EMOBN ESX EX3 F5P FPL FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IAO IEA IGS IHR IHW INH INR IOV IPY ISE ISR ITC K6- KB. KQ8 L6V LK5 LK8 M0K M1P M48 M7P M7R M7S M~E NAPCQ O5R O5S OK1 OVT P2P P62 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PTHSS PV9 PYCSY RNS RPM RZL SV3 TR2 UKHRP WOQ WOW ~02 ~KM ALIPV BBORY CGR CUY CVF ECM EIF IPNFZ NPM RIG 3V. 7QG 7QL 7QO 7SN 7SS 7T5 7TG 7TM 7U9 7XB 8FD 8FK AZQEC C1K DWQXO ESTFP FR3 GNUQQ H94 K9. KL. M7N P64 PKEHL PQEST PQUKI PRINS RC3 7X8 PUEGO 5PM AAPBV ABPTK |
| ID | FETCH-LOGICAL-c526t-c4642646e53e79ab8f38aa2e1e1cfd773d250be20b1c89d4eb9818e7e1dfa35f3 |
| IEDL.DBID | FPL |
| ISICitedReferencesCount | 25 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000356932500006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1932-6203 |
| IngestDate | Sun Nov 05 00:20:34 EDT 2023 Mon Nov 10 04:33:31 EST 2025 Tue Nov 04 02:01:55 EST 2025 Wed Oct 01 14:08:21 EDT 2025 Mon Oct 20 01:24:22 EDT 2025 Thu Apr 03 06:55:24 EDT 2025 Sat Nov 29 06:07:07 EST 2025 Tue Nov 18 22:28:59 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Language | English |
| License | This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. Creative Commons Attribution License |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c526t-c4642646e53e79ab8f38aa2e1e1cfd773d250be20b1c89d4eb9818e7e1dfa35f3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Conceived and designed the experiments: BM PB FB SB DL HR DS FN. Performed the experiments: BM PB FB SB DL HR DS FN. Analyzed the data: BM PB FB SB DL HR DS FN. Contributed reagents/materials/analysis tools: BM PB FB SB DL HR DS FN. Wrote the paper: BM PB FB SB DL HR DS FN. Competing Interests: Beat Müllhaupt has served as an advisory board member for Roche, MSD, Janssen Therapeutics, AbbVie, Boehringer Ingelheim, Gilead and BMS; as a consultant for Gilead and AbbVie; and has received research grants from Roche and Gilead. Philip Bruggmann has served as advisor and speaker for, and has received project and research grants from Roche, MSD, Janssen, AbbVie, Gilead, Viif and BMS. Sarah Blach and Homie Razavi are employees of the Center for Disease Analysis (CDA), Louisville, Colorado, USA. David Semela has served as a consultant for Gilead, an advisor for Roche, MSD, Gilead, Novartis, Janssen and Boehringer Ingelheim and has received an unrestricted research grant from Roche. Francesco Negro has served as advisor for MSD, Gilead, Novartis, Bristol Myers Squibb, AbbVie and Janssen and has received unrestricted research grants from Roche and Gilead. Florian Bihl and Daniel Lavanchy have no conflicts of interest to declare. As part of this project, none of the authors were part of any activities related to patents, product development or marketed products. The funding of this project by Gilead does not alter the authors’ adherence to PLOS ONE policies on sharing data and materials. |
| OpenAccessLink | http://dx.doi.org/10.1371/journal.pone.0125214 |
| PMID | 26107467 |
| PQID | 1691039531 |
| PQPubID | 1436336 |
| ParticipantIDs | plos_journals_1691039531 doaj_primary_oai_doaj_org_article_f1eb1a93b2254aa5a9edb84f71610c72 pubmedcentral_primary_oai_pubmedcentral_nih_gov_4480969 proquest_miscellaneous_1691594772 proquest_journals_1691039531 pubmed_primary_26107467 crossref_primary_10_1371_journal_pone_0125214 crossref_citationtrail_10_1371_journal_pone_0125214 |
| PublicationCentury | 2000 |
| PublicationDate | 2015-06-24 |
| PublicationDateYYYYMMDD | 2015-06-24 |
| PublicationDate_xml | – month: 06 year: 2015 text: 2015-06-24 day: 24 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: San Francisco – name: San Francisco, CA USA |
| PublicationTitle | PloS one |
| PublicationTitleAlternate | PLoS One |
| PublicationYear | 2015 |
| Publisher | Public Library of Science Public Library of Science (PLoS) |
| Publisher_xml | – name: Public Library of Science – name: Public Library of Science (PLoS) |
| References | BR Edlin (ref2) 2011; 474 ref15 ref14 ND Mdege (ref35) 2013; 28 ref30 D Lavanchy (ref3) 2011; 17 F Dubois-Arber (ref28) 2008; 13 A Aronsohn (ref36) 2014; 59 ref17 BD Smith (ref37) 2012; 61 (ref20) 2011 L Degenhardt (ref24) 2006; 82 T Poynard (ref7) 2002; 122 M Sagmeister (ref13) 2002; 14 (ref18) 2013 K Mohd Hanafiah (ref19) 2013; 57 BM Mathers (ref23) 2013; 91 S Aleman (ref8) 2013; 57 GL Armstrong (ref6) 2000; 31 (ref34) 2008 ref22 ref21 M Hickman (ref25) 2009; 31 P Bruggmann (ref12) 2014; 21 R Fretz (ref9) 2013; 143 DM Evon (ref31) 2007; 52 GL Armstrong (ref16) 2006; 144 C Nordt (ref26) 2010; 29 S Arora (ref33) 2011; 364 JA Morrill (ref32) 2005; 20 H Razavi (ref11) 2014; 21 H Razavi (ref29) 2013; 57 M Cornberg (ref10) 2011; 31 (ref1) 2006; 01 JB Wong (ref4) 2000; 90 KN Ly (ref5) 2012; 156 L Prasad (ref27) 2007; 36 |
| References_xml | – volume: 52 start-page: 3251 year: 2007 ident: ref31 article-title: High deferral rates and poorer treatment outcomes for HCV patients with psychiatric and substance use comorbidities publication-title: Dig Dis Sci doi: 10.1007/s10620-006-9669-0 – volume: 31 start-page: 777 year: 2000 ident: ref6 article-title: The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States publication-title: Hepatology doi: 10.1002/hep.510310332 – volume: 474 start-page: S18 year: 2011 ident: ref2 article-title: Perspective: test and treat this silent killer publication-title: Nature doi: 10.1038/474S18a – volume: 122 start-page: 1303 year: 2002 ident: ref7 article-title: Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C publication-title: Gastroenterology doi: 10.1053/gast.2002.33023 – volume: 31 start-page: 30 issue: Suppl 2 year: 2011 ident: ref10 article-title: A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel publication-title: Liver Int doi: 10.1111/j.1478-3231.2011.02539.x – volume: 20 start-page: 754 year: 2005 ident: ref32 article-title: Barriers to the treatment of hepatitis C. Patient, provider, and system factors publication-title: J Gen Intern Med doi: 10.1111/j.1525-1497.2005.0161.x – volume: 59 start-page: 13 year: 2014 ident: ref36 article-title: Expanding access to hepatitis C virus care: a call to deconstruct individualized therapy publication-title: Hepatology doi: 10.1002/hep.26590 – volume: 57 start-page: 1333 year: 2013 ident: ref19 article-title: Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence publication-title: Hepatology doi: 10.1002/hep.26141 – year: 2011 ident: ref20 article-title: Permanent foreign resident population by nationality by country and Canton, 1990–2010 publication-title: Permanent foreign resident population by nationality by country and Canton, 1990–2010 – volume: 364 start-page: 2199 year: 2011 ident: ref33 article-title: Outcomes of treatment for hepatitis C virus infection by primary care providers publication-title: N Engl J Med doi: 10.1056/NEJMoa1009370 – volume: 17 start-page: 107 year: 2011 ident: ref3 article-title: Evolving epidemiology of hepatitis C virus publication-title: Clin Microbiol Infect doi: 10.1111/j.1469-0691.2010.03432.x – volume: 57 start-page: 230 year: 2013 ident: ref8 article-title: A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis publication-title: Clin Infect Dis doi: 10.1093/cid/cit234 – volume: 36 start-page: 731 year: 2007 ident: ref27 article-title: Cohort profile: The Swiss hepatitis C cohort study (SCCS) publication-title: Int J Epidemiol doi: 10.1093/ije/dym096 – volume: 01 start-page: 1 year: 2006 ident: ref1 article-title: State of the art of new vaccine research and development – ident: ref22 – volume: 31 start-page: 374 year: 2009 ident: ref25 article-title: Assessing IDU prevalence and health consequences (HCV, overdose and drug-related mortality) in a primary care trust: implications for public health action publication-title: J Public Health (Oxf) doi: 10.1093/pubmed/fdp067 – volume: 91 start-page: 102 year: 2013 ident: ref23 article-title: Mortality among people who inject drugs: a systematic review and meta-analysis publication-title: Bull World Health Organ doi: 10.2471/BLT.12.108282 – volume: 21 start-page: 5 issue: Suppl 1 year: 2014 ident: ref12 article-title: Historical epidemiology of hepatitis C virus (HCV) in selected countries publication-title: J Viral Hepat doi: 10.1111/jvh.12247 – volume: 13 year: 2008 ident: ref28 article-title: Trends in drug consumption and risk of transmission of HIV and hepatitis C virus among injecting drug users in Switzerland, 1993–2006 publication-title: Euro Surveill doi: 10.2807/ese.13.21.18881-en – ident: ref17 – ident: ref15 – volume: 61 start-page: 1 year: 2012 ident: ref37 article-title: Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965 publication-title: MMWR Recomm Rep – volume: 143 start-page: 0 year: 2013 ident: ref9 article-title: Hepatitis B and C in Switzerland-healthcare provider initiated testing for chronic hepatitis B and C infection publication-title: Swiss Med Wkly – ident: ref30 – volume: 57 start-page: 2164 year: 2013 ident: ref29 article-title: Chronic hepatitis C virus (HCV) disease burden and cost in the United States publication-title: Hepatology doi: 10.1002/hep.26218 – volume: 21 start-page: 34 issue: Suppl 1 year: 2014 ident: ref11 article-title: The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm publication-title: J Viral Hepat doi: 10.1111/jvh.12248 – volume: 90 start-page: 1562 year: 2000 ident: ref4 article-title: Estimating future hepatitis C morbidity, mortality, and costs in the United States publication-title: Am J Public Health doi: 10.2105/AJPH.90.10.1562 – volume: 28 start-page: 223 year: 2013 ident: ref35 article-title: The effectiveness and cost implications of task-shifting in the delivery of antiretroviral therapy to HIV-infected patients: a systematic review publication-title: Health Policy Plan doi: 10.1093/heapol/czs058 – ident: ref21 – start-page: 1 year: 2008 ident: ref34 article-title: Task Shifting: Global Recommendations and Guidelines publication-title: Task Shifting: Global Recommendations and Guidelines – year: 2013 ident: ref18 article-title: Number of acute cases of hepatitis C in Switzerland by reporting year: FOPH/ID/EPI/RIC publication-title: Number of acute cases of hepatitis C in Switzerland by reporting year: FOPH/ID/EPI/RIC – volume: 29 start-page: 540 year: 2010 ident: ref26 article-title: Combined effects of law enforcement and substitution treatment on heroin mortality publication-title: Drug Alcohol Rev doi: 10.1111/j.1465-3362.2009.00167.x – volume: 144 start-page: 705 year: 2006 ident: ref16 article-title: The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 publication-title: Ann Intern Med doi: 10.7326/0003-4819-144-10-200605160-00004 – volume: 14 start-page: 25 year: 2002 ident: ref13 article-title: Simulation of hepatitis C based on a mandatory reporting system publication-title: Eur J Gastroenterol Hepatol doi: 10.1097/00042737-200201000-00006 – volume: 82 start-page: iii56 issue: Suppl 3 year: 2006 ident: ref24 article-title: Using cohort studies to estimate mortality among injecting drug users that is not attributable to AIDS publication-title: Sex Transm Infect – volume: 156 start-page: 271 year: 2012 ident: ref5 article-title: The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007 publication-title: Ann Intern Med doi: 10.7326/0003-4819-156-4-201202210-00004 – ident: ref14 |
| SSID | ssj0053866 |
| Score | 2.3102286 |
| Snippet | Chronic hepatitis C virus infection is a major cause of liver disease in Switzerland and carries a significant cost burden. Currently, only conservative... Background Chronic hepatitis C virus infection is a major cause of liver disease in Switzerland and carries a significant cost burden. Currently, only... BackgroundChronic hepatitis C virus infection is a major cause of liver disease in Switzerland and carries a significant cost burden. Currently, only... Background Chronic hepatitis C virus infection is a major cause of liver disease in Switzerland and carries a significant cost burden. Currently, only... |
| SourceID | plos doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | e0125214 |
| SubjectTerms | Adolescent Adult Antiviral agents Antiviral Agents - therapeutic use Biopsy Chronic infection Economic models Economics Effectiveness Estimates Female Gastroenterology Hepacivirus - pathogenicity Hepatitis Hepatitis C Hepatitis C, Chronic - economics Hepatitis C, Chronic - epidemiology Hepatitis C, Chronic - therapy Hepatology Hospitals Humans Infections Liver Liver cirrhosis Liver Cirrhosis - economics Liver Cirrhosis - epidemiology Liver Cirrhosis - therapy Liver diseases Liver Transplantation Liver transplants Male Medical treatment Middle Aged Modelling Mortality Population Primary care Public health Switzerland Systematic review Viruses |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Ba90wDBaj9LDLWLt1zdYOD3pYD2mT2IntY1daBitlsK30FhxHZoGSV17e26C_vnLsPPpKoZdecogdx5ZkWcLSJ4CDlmTClVqnonAZPZCnqjI8RSe5kVpl2oxVSy7k5aW6vtY_H5T68jFhAR44EO7Y5aRNjOYNCZ4wpjQa20YJR3Z-nlk5al-yeiZnKuhg2sVVFRPluMyPI1-Obmc9HpFKpjNLrB1EI16_xze9mQ1P2ZqPQyYfnEHnb-FNNB7ZSZj0FrzCfhu24vYc2NeIIX34Dn74Gmc-05yRgcdCrhEzfcumRGQW8hfYzFGrj6pedAM7ZVfdfDmwrme__neLu5AJ_B7-nJ_9Pv2exroJqS2LapFaUXk7p8KSo9SmUY4rYwrMMbeulZK3ZPc0WGRNbpVuBTaajm2UmLfO8NLxHdjoiVK7wEj9IG9shgq5QFuoxlkfZZXTEEY6lQCfiFjbCCrua1vc1ONNmSTnIpCm9qSvI-kTSFdf3QZQjWf6f_P8WfX1kNjjCxKUOgpK_ZygJLDruTv9YKg9TFDGNSmhBPYmjj_d_GXVTJvP36iYHmfL0KfUQvrRPwQBWU2SXNOxlksCck101lax3tJ3f0eAb3KZybPUH19i2Z_gNdl4pY9uK8QebCzmS9yHTfuPxGr-edw193bAHqM priority: 102 providerName: Directory of Open Access Journals – databaseName: Biological Science Database dbid: M7P link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3di9QwEB_0FBREvfXjVk-J4IM-9K5t2iZ5Ej08BOU48IN7K2k60cLRrttdBf96Z9p0deXQB1_60EzTtDOZzCQzvwF4WpNM-NyYKEt9TBeUkS6sjNAraZXRsbFD1ZJ36uREn52Z07Dh1oewykknDoq67hzvkR8yqEssDYnMi8XXiKtG8elqKKFxGa4wSoIcQvdOJ01Mc7koQrqcVMlh4M7BomvxgBQzrVzZ1nI0oPYzyul5119kcf4ZOPnbSnR863-_4TbcDDaoeDkKzS5cwnYG16YU5X4GN8bNPDHmKM1gN2iAXjwLMNXP78BbLqPGyeyCbMhAKmxbi6kjMaZIiM5TKwdur5peHIlPzXLdi6YV7783qx9jsvFd-Hj8-sPRmyiUZohcnharyGUFm1IF5hKVsZX2UlubYoKJ87VSsibTqsI0rhKnTZ1hZcgyQIVJ7a3MvbwHOy2xYQ8EaTiUlYtRo8zQpbryjgO5EurCKq_nICcOlS7glnP5jPNyOIxT5L-Mv61kvpaBr3OINk8tRtyOf9C_YuZvaBl1e7jRLT-XYRKXPqGVzRpZkRLMrM2twbrSmSefM4mdSuewx6IzvaAvfzF8DvuTSFzc_GTTTPObD21si916pMlNprj3-6P0bQZJ3u9QLmYOaksut75iu6VtvgwY4uSVk_NqHvx9WA_hOhmIOYfGpdk-7KyWa3wEV903Epjl42Gy_QTGojUF priority: 102 providerName: ProQuest |
| Title | Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/26107467 https://www.proquest.com/docview/1691039531 https://www.proquest.com/docview/1691594772 https://pubmed.ncbi.nlm.nih.gov/PMC4480969 https://doaj.org/article/f1eb1a93b2254aa5a9edb84f71610c72 http://dx.doi.org/10.1371/journal.pone.0125214 |
| Volume | 10 |
| WOSCitedRecordID | wos000356932500006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: DOA dateStart: 20060101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M~E dateStart: 20060101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Agriculture Science Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M0K dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/agriculturejournals providerName: ProQuest – providerCode: PRVPQU databaseName: Biological Science Database (ProQuest) customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M7P dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Engineering Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M7S dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com providerName: ProQuest – providerCode: PRVPQU databaseName: Environmental Science Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: PATMY dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com/environmentalscience providerName: ProQuest – providerCode: PRVPQU databaseName: Materials Science Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: KB. dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com/materialsscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest advanced technologies & aerospace journals customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: P5Z dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/hightechjournals providerName: ProQuest – providerCode: PRVPQU databaseName: Proquest Central customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: BENPR dateStart: 20061201 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Health & Medical Collection customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: 7X7 dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Nursing & Allied Health Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: 7RV dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database (ProQuest) customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: 8C1 dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: PIMPY dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVATS databaseName: Public Library of Science (PLoS) Journals Open Access customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: FPL dateStart: 20060101 isFulltext: true titleUrlDefault: http://www.plos.org/publications/ providerName: Public Library of Science |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlR1Nb9Mw9IltHJAQsPGxwKiMxAEO6ZI4ie0jrVaBulXRBlPhEjmJLSJN6dS0IPHreXacQqdNiMs7xHbi2O_Tfh8AbyvECZ0I4ceRDhAo6vNUUl9pRiUTPBDSVi05ZbMZn89F9sdQvHGDT1l47NZ0eL1o1BDZKcqbeAf2IpqmxoVrkp32nBdpN01deNxdI7fEj83Sb7KaXi3a2zTMm46Sf0meyeP_nfMTeOR0TPKhQ4p9uKeaA3jYHdCRLu7oAPYdVbfknUs9_f4pTE1pNBOgTlAvdF2JbCrSxy-TLuyBLDS2GmfsVd2SMbmsl-uW1A25-FmvfnUBxM_gy-Tk8_ij78ot-GUSpSu_jFOjHqUqoYoJWXBNuZSRClVY6ooxWqG6VKgoKMKSiypWhUBpr5gKKy1poulz2G3whw-BINdStCgDxRWNVRnxQpfGOSvEV0imuQe034W8dLnITUmMq9xesDG0Sbqlys0K5m4FPfA3o667XBz_6D8yG7zpazJp2we4VbkjzFyHKK2koAUytljKRApVFTzWaEeGQckiDw4NevQfaHOTXSigAnmXB0c9ytze_GbTjDRrLmJkoxbrrk8iYmbe_qLDsM0k0aK1JWA8YFu4t_UX2y1N_d3mBUdLGw1S8fLuGb-CB6jwJcbVLYqPYHe1XKvXcL_8gciyHMAOO780cM4s5Aj5OBzA3uhklp0P7HnFwJIcwuloiPAsmBrIMgsvEGbJNxyRfTrLvv4GB0IsHg |
| linkProvider | Public Library of Science |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Nb9QwEB2VglQkBHSBNlDASCDBIW0SO3F8QAgKVatdVghK1VtwHLtEqpJls0sFP4rfyDhxFhZVcOqBSw6x4zj285txPB8AjwvEhImF8FlkArxo6qeJpL42nEou0kDINmvJiI_H6fGxeLcCP3pfGGtW2XNiS9RFrew_8h0b1CWgAiHzYvLFt1mj7Olqn0Kjg8VQfzvDLVvz_OA1zu-TKNp7c7i777usAr6Ko2TmK5ZYLSDRMdVcyDw1NJUy0qEOlSk4pwVqBbmOgjxUqSiYzgUKNc11WBhJY0Ox3UtwGXk8tCZk_P1Rz_zIHUni3PMoD3ccGrYndaW3URCgpGRL4q_NEmCjqp7WzXka7p-Gmr9Jvr0b_9uY3YTrTscmL7tFsQ4ruhrAWu-C3QzgWvezknQ-WANYdwzXkKcuDPezWzC0aeKssz5BHdlVJbIqSN8Q6VxASG2w1Bqmz8qG7JKjcjpvSFmRD2fl7HvnTH0bPl7IB9-B1QqnfRMIMrimuQp0qinTKkpzo6yhWohNSG5SD2iPiEy5uOw2Pchp1h42ctyfdcOWWRxlDkce-IunJl1ckn_Uf2XBtqhro4q3N-rpSeZIKjMhSm4paI4kz6SMpdBFnjKDe-owUDzyYNNCtX9Bk_0CmAdbPQTPL360KEb-sodSstL1vKsTC8Zt6xsd2hedxN19mw7HA760Dpa-YrmkKj-3MdIZQ5pJxN2_d-shrO0fvh1lo4Px8B5cRWU4tmaAEduC1dl0ru_DFfUVwTN90C50Ap8uepX8BN3Tk44 |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VggAJAV0eDRQwEkhwSDeJnTg-IARbVlRbrSoBVW_BcWyIVCXLZpcKfhq_jnHiLCyq4NQDlxxix3GSb74Zx_MAeFIgJkwshM8iE-BBUz9NJPW14VRykQZCtlVLDvh0mh4fi8MN-NHHwli3yp4TW6IuamX_kQ9tUpeACoTM0Di3iMO98cvZF99WkLI7rX05jQ4iE_3tFJdvzYv9PfzWT6No_Ob96K3vKgz4Ko6Sha9YYi2CRMdUcyHz1NBUykiHOlSm4JwWaCHkOgryUKWiYDoXqOA012FhJI0NxXEvwEVOEcU2Sn20ci9BHkkSF6pHeTh0yNid1ZXeRaWAWpOtqcK2YoDNsHpSN2dZu386bf6mBcc3_uf3dxOuO9ubvOqEZQs2dDWAK31odjOAa91PTNLFZg1gyzFfQ5659NzPb8HElo-zQfwEbWfXlciqIP1ApAsNIbXBVuuwvigbMiJH5XzZkLIi707LxfcuyPo2fDiXB74DmxVCYBsIMrumuQp0qinTKkpzo6wDW4hDSG5SD2iPjky5fO22bMhJ1m5Ccly3da8ts5jKHKY88FdXzbp8Jf_o_9oCb9XXZhtvT9TzT5kjr8yEqNGloDmSP5MylkIXecoMrrXDQPHIg20L2_4GTfYLbB7s9HA8u_nxqhl5zW5WyUrXy65PLBi3o9_tkL-aJK762zI5HvA1mVh7ivWWqvzc5k5nDOknEff-Pq1HcBmFIzvYn07uw1W0kWPrHRixHdhczJf6AVxSXxE784etzBP4eN5C8hM7V5vp |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Modeling+the+Health+and+Economic+Burden+of+Hepatitis+C+Virus+in+Switzerland&rft.jtitle=PloS+one&rft.au=M%C3%BCllhaupt%2C+Beat&rft.au=Bruggmann%2C+Philip&rft.au=Bihl%2C+Florian&rft.au=Blach%2C+Sarah&rft.date=2015-06-24&rft.pub=Public+Library+of+Science&rft.eissn=1932-6203&rft.volume=10&rft.issue=6&rft_id=info:doi/10.1371%2Fjournal.pone.0125214&rft.externalDocID=1691039531 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon |